Results 61 to 70 of about 4,697 (156)

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

BACKGROUNDWhether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown.METHODSIn this ...
Seymour, John F., Skarbnik, Alan, Eom, Ki-Seong, de Borja, Marianne, Wach, Malgorzata, Kater, Arnon Philip, Munugalavadla, Veerendra, Illes, Arpad, Brown, Jennifer R, Jurczak, Wojciech, Pavlovsky, Miguel Arturo, Miller, Kara, Brown, Jennifer R., Aw, Andrew, Simkovic, Martin, Lysak, Daniel, Owen, Carolyn, Tedeschi, Alessandra, Eichhorst, Barbara, Seymour, John F, Ghia, Paolo, AMPLIFY investigators, AMPLIFY investigators, Yu, Ting   +22 more
core   +1 more source

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

BMC Cancer, 2019
Background Transformation of chronic lymphocytic leukaemia (CLL) to diffuse large B-cell lymphoma (DLCBL) type Richter’s syndrome (RS) carries a dismal prognosis.
Niamh Appleby, Toby A. Eyre, Maite Cabes, Aimee Jackson, Rebecca Boucher, Francesca Yates, Sonia Fox, Andrew Rawstron, Peter Hillmen, Anna Schuh   +9 more
doaj   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor [PDF]

, 2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic ...
Delong Liu, Jingjing Wu, Mingzhi Zhang
core   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments (PQRST)” Trial

American Journal of Hematology, Volume 101, Issue 9, Page 2280-2287, September 2026.
ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton, Lynn Onstad, Paul A. Carpenter, Joseph Pidala, George Chen, Corey Cutler, Najla El Jurdi, Nosha Farhadfar, Mark Juckett, Carrie L. Kitko, Catherine J. Lee, Stephanie J. Lee   +11 more
wiley   +1 more source

A functional prognostic model predicts progression‐free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax

HemaSphere, Volume 10, Issue 9, September 2026.
Abstract Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations.
Johanne U. Hermansen, Weikaixin Kong, Andrea M. Brodersen, Yanping Yin, Aleksandra Urban, Idun D. Rein, Liye He, Rudi Agius, Rebecca S. Teglgaard, Juho Rousu, Christian Brieghel, Sabina Kersting, Mark‐David Levin, Hoa T. T. Tran, Mattias Mattsson, Juha Ranti, Gerrit‐Jan Veldhuis, Caspar da Cunha‐Bang, Rogier Mous, Julie Dubois, Arnon P. Kater, Jorrit M. Enserink, Carsten U. Niemann, Tero Aittokallio, Sigrid S. Skånland   +24 more
wiley   +1 more source

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

Journal of Comparative Effectiveness Research
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley   +9 more
doaj   +1 more source

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice

Frontiers in Immunology, 2019
Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 ...
Caroline E. O'Riordan, Gareth S. D. Purvis, Debora Collotta, Fausto Chiazza, Bianka Wissuwa, Bianka Wissuwa, Sura Al Zoubi, Lara Stiehler, Lara Stiehler, Lukas Martin, Lukas Martin, Sina M. Coldewey, Sina M. Coldewey, Massimo Collino, Christoph Thiemermann   +14 more
doaj   +1 more source

Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B‐Cell Lymphoma: A Scoping Review

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Early identification of refractory disease remains a significant unmet clinical need in patients with diffuse large B‐cell lymphoma (DLBCL). This scoping review was conducted to assess the current knowledge on the use of circulating tumor DNA (ctDNA), either alone or in combination with immune markers, as predictive tools for treatment outcome
Ailin McMahon, Elizabeth J. Ryan, Sarah Dillon, Ruth Clifford   +3 more
wiley   +1 more source